医学
免疫失调
自身免疫性淋巴增生综合征
免疫学
自身免疫
痹症科
淋巴增殖性病變
恶性肿瘤
免疫系统
Fas配体
淋巴瘤
内科学
Fas受体
细胞凋亡
化学
生物化学
程序性细胞死亡
作者
Christopher Failing,Jennifer R. Blase,Kelly Walkovich
标识
DOI:10.1016/j.rdc.2023.07.001
摘要
As a disorder of immune dysregulation, autoimmune lymphoproliferative syndrome (ALPS) stems from pathogenic variants in the first apoptosis signal-mediated apoptosis (Fas) and Fas-ligand pathway that result in elevations of CD3+ TCRαβ+ CD4- CD8- T cells along with chronic lymphoproliferation, a heightened risk for malignancy, and importantly for the rheumatologist, increased risk of autoimmunity. While immune cytopenias are the most encountered autoimmune phenomena, there is increasing appreciation for ocular, musculoskeletal, pulmonary and renal inflammatory manifestations similar to more common rheumatology diseases. Additionally, ALPS-like conditions that share similar clinical features and opportunities for targeted therapy are increasingly recognized via genetic testing, highlighting the need for rheumatologists to be facile in the recognition and diagnosis of this spectrum of disorders. This review will focus on clinical and laboratory features of both ALPS and ALPS-like disorders with the intent to provide a framework for rheumatologists to understand the pathophysiologic drivers and discriminate between diagnoses.
科研通智能强力驱动
Strongly Powered by AbleSci AI